CIRIUM
29.12.2020 08:02:09 CET | Business Wire | Press release
Global aviation data firm Cirium today released its new Airline Insights Review 2020 which reveals the shocking impact on aviation of worldwide travel restrictions to curb COVID-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201228005254/en/
The report shows that the pandemic and its consequences wiped out 21 years of global passenger traffic growth in a matter of months, reducing traffic this year to levels last seen in 1999. In comparison to last year, passenger traffic is estimated to be down 67% in 2020.
At the peak of the disruption in April, scheduled passenger flights dropped significantly to just 13,600 globally on April 25, compared to the year’s busiest day on January 3 when Cirium tracked over 95,000 scheduled passenger flights globally. This marks an extraordinary 86% reduction in flights.
From January to December airlines operated 49% fewer flights in 2020 compared to 2019 – down from 33.2 million flights to just 16.8 million (to December 20).
Domestic travel was down 40% this year, from 21.5 million flights in 2019, while international flights suffered an even more precipitous drop as they were 68% below the 11.7 million flights tracked the year before.
Jeremy Bowen, CEO of Cirium, said: “This severe setback shows the true extent of the challenge faced by the struggling aviation sector as it has sought to reset itself in the new post COVID-19 era.”
“Whereas this time last year we were celebrating the on-time performance of global carriers, this year is dramatically different. Most global airlines were largely on time in 2020; it’s just a shame that the traveling public, airlines and aviation firms worldwide didn’t benefit.
“The factors which usually cause delay, such as congested airspace, taxiways and late connecting passengers simply did not exist in 2020.”
The Cirium Airline Insights Review 2020 replaces Cirium’s annual On-Time Performance Review which for more than a decade has identified the world’s best performing airlines and airports for on-time flight operations.
NEW AIRLINE INSIGHTS REVIEW: FLIGHTS FLOWN DRAMATICALLY DOWN
Global passenger traffic figures reveal a plunge of over two thirds (67%) versus the previous year, with Asia-Pacific continuing to handle over a third of world passenger traffic.
The majority of the scheduled passenger flights flown this year have been domestic – totaling 13 million (77%) with a mere 3.8 million (23%) flying internationally, due to closed borders and limited business travel.
Cirium data analysis recorded Southwest Airlines operating the most flights globally (and in North America), with 854,800 flights in total. Meanwhile, China Southern Airlines (487,700 flights) topped the tables in the Asia-Pacific, Ryanair in Europe (205,000 flights), Azul in Latin America (134,000 flights) and Qatar Airways (82,400 flights) in the Middle East and Africa.
On the ground, Atlanta was the world’s busiest airport, handling over 245,000 arriving flights during 2020, while the world’s busiest air route in both directions was within South Korea, between Seoul and the island of Jeju with 70,700 flights operated.
Forward planning for airlines has dramatically contracted from six- to 12-months for flight scheduling to just six- to eight-weeks – forcing carriers to be nimbler and adapt with greater speed to the rapidly changing rules and travel restrictions around the world.
FLEETS IN STORAGE (BUT NOT THE A320)
As airlines have been forced to drastically reduce the number of aircraft still in service, those still flying are operating significantly fewer hours.
For example, narrowbody aircraft operated just six to seven hours a day in Q3 2020 compared to nine to 10 hours a day in the same period last year.
While up to 30% of the global passenger fleet remains in storage there are signs of recovery on the horizon, with only 10% of short-haul Airbus A320neo aircraft currently in storage showing narrowbody aircraft leading the recovery and domestic and short-haul travel returning first.
With domestic and short-haul services ruling the day, the world’s most used aircraft type was the Airbus A320 with Cirium tracking 5.49 million flights throughout 2020.
SEVEN TRENDS IDENTIFIED BY CIRIUM
“Airlines will have a way before returning to 2019 levels particularly as international travel is significantly down and showing only slow signs of recovery, mainly China and Southeast Asia,” Jeremy Bowen added.
“But Cirium is confident aviation will weather this difficult and terrible year and emerge in better shape – with younger more fuel-efficient aircraft and right-sized fleets – to gradually navigate their way to recovery in the years ahead.”
The seven key trends outlined by The Cirium Airline Insights Review 2020 for next year include:
- The consolidation of airlines , particularly in Asia-Pacific where more domestic competitors will merge or be acquired.
- New-generation aircraft like the A320neo and the return of the 737 Max, will provide reduced operating costs.
- Surplus aircraft will be retired and the Boeing 747 and the Airbus A380 are projected to support the rising demand in the denser leisure markets.
- In Q4 we saw a 78% plunge in bookings compared to the same period last year – this will naturally change the way the industry forecasts demand , we are seeing on-line search and sentiment becoming the primary indicators to calculate demand.
- Airlines will need to deploy more dynamic scheduling with the increased volatility of flight scheduling, as the booking window has fallen from six- to 12-months to just six- to eight-weeks.
- The implementation of AI technology will accelerate to automate the traveler experience and real-time proactive information will become more critical.
- Aircraft leasing will push past 50% becoming the major manner in which aircraft are financed .
To read the full Cirium Airline Insights Review 2020 – click here.
Bowen thanked the OTP board members comprised of Henry Harteveldt at Atmosphere Research group and Dr. Mario Hardy at Pacific Asia Travel Association (PATA) for their insights and contributions to the Airline Insight Review 2020.
For further information please visit www.cirium.com and follow Cirium updates via LinkedIn and Twitter .
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201228005254/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press release
The collaboration leverages Elevate Farms’ proprietary vertical farming technology reducing water consumption, land usage and carbon emissions. Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland req
SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press release
Revenue of $9.45 billion increased 5% sequentially and 6% year on year GAAP EPS of $0.49 decreased 6% sequentially and 2% year on year EPS, excluding charges and credits, of $0.64 increased 16% sequentially and decreased 7% year on year Net income attributable to SLB of $735 million decreased 6% sequentially and 1% year on year Adjusted EBITDA of $2.07 billion increased 9% sequentially and was essentially flat year on year Cash flow from operations was $1.51 billion and free cash flow was $828 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5
EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press release
EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
